CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

International Journal of Endocrinology - United States
doi 10.1155/2018/1742951
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Journal of Cancer
Oncology
2017English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Distinctive Gene Expression Patterns in Human Mammary Epithelial Cells and Breast Cancers

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1999English

The Association of Genomic Lesions and PD-1/PD-L1 Expression in Resected Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2018English

The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: A Meta-Analysis

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2019English

Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors

Asian Pacific Journal of Cancer Prevention
2019English

PD-1- And CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Science Translational Medicine
Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy